We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Subcutaneous ICD Protects the Beating Heart

By HospiMedica International staff writers
Posted on 04 May 2016
A novel implantable cardioverter defibrillator (ICD) uses a subcutaneous electrode to analyze heart rhythm, in order to effectively protect patients from sudden cardiac arrest (SCA), while leaving the heart and vasculature untouched.

The EMBLEM S-ICD System provides a new solution to protect patients from SCA without touching the heart, avoiding potential complications associated with transvenous implantable defibrillators. More...
While the EMBLEM S-ICD System utilizes a pulse generator--similar to those in a transvenous ICD--it differs in that it uses a subcutaneous electrode to analyze the heart rhythm, rather than individual beats to effectively sense, discriminate, and convert ventricular fibrillation (VF) and ventricular tachycardia (VT).

The EMBLEM S-ICD System also includes SMART Pass technology, which helps ensure patients receive therapy from the device only when necessary by enhancing a proprietary algorithm that identifies and classifies heart rhythm for effective arrhythmia treatment. A second feature, the atrial fibrillation (AF) monitor, is designed to help physicians make more informed treatment decisions. The EMBLEM S-ICD family is a product of Boston Scientific Corporation (Natick, MA, USA), and has received the European Community CE mark of approval.

In Europe, the EMBLEM magnetic resonance imaging (MRI) S-ICD System has been designated as an Image Ready MR-conditional device, and is labeled safe for use in a MRI setting. Patients receiving the EMBLEM MRI S-ICD System, as well as patients who previously were implanted with an EMBLEM S-ICD system are now able to undergo full-body MR scans safely in 1.5 Tesla environments, when conditions of use are met. Boston Scientific is actively pursuing U.S. Food and Drug Administration (FDA) approval of the systems.

“These approvals give reassurance to physicians and their patients that they have access to any future MR scan needs, and underscores the Boston Scientific commitment to gain MR-conditional labeling on high-voltage devices that are being implanted today,” said Kenneth Stein, MD, chief medical officer of rhythm management at Boston Scientific. “Further, the EMBLEM S-ICD System is a compelling treatment option for the majority of ICD-indicated patients that provides protection from cardiac arrest without invading the heart and blood vessels.”

Related Links:
Boston Scientific


New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Tourniquet System
heidi– mein Tourniquet
New
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.